This inventor holds 4 USPTO granted patents and 18 published patent applications and 8 EPO patents. Top assignees: Jazz Pharmaceuticals Research UK Limited, Gw Research Limited. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovations of Daniel Adam Checketts
Introduction
Daniel Adam Checketts is a notable inventor based in Cambridgeshire, GB. He has made significant contributions to the field of medicine, particularly in the treatment of epilepsy. With a total of 4 patents to his name, Checketts is recognized for his innovative approaches to utilizing cannabidiol (CBD) in therapeutic applications.
Latest Patents
Checketts' latest patents focus on the use of cannabidiol in the treatment of epilepsy. One patent addresses the use of CBD in patients with childhood-onset epilepsy who are also taking caffeine. This invention emphasizes the need for caution, suggesting that the doses of CBD and/or caffeine may need to be reduced, and patients should be monitored for potential side effects. The preferred form of CBD is a highly purified extract, ensuring that it contains more than 95% CBD while minimizing the presence of tetrahydrocannabinol (THC) to no more than 0.15%.
Another significant patent involves the use of CBD for treating seizures associated with Rett syndrome, a rare epilepsy syndrome. This invention outlines the types of seizures that can be treated, including tonic, tonic-clonic, absence, and focal seizures with impairment. The recommended dosage of CBD ranges from 5 mg/kg/day to 50 mg/kg/day, showcasing Checketts' commitment to developing effective treatment options for patients with complex medical needs.
Career Highlights
Daniel Adam Checketts is currently employed at Jazz Pharmaceuticals Research UK Limited, where he continues to advance his research in the field of epilepsy treatment. His work is characterized by a strong focus on the therapeutic potential of cannabinoids, particularly CBD, in addressing challenging medical conditions.
Collaborations
Checketts collaborates with Kevin James Craig, contributing to the innovative research environment at Jazz Pharmaceuticals. Their combined expertise enhances the development of new therapeutic strategies for epilepsy and related disorders.
Conclusion
Daniel Adam Checketts is a pioneering inventor whose work in the field of cannabidiol research is making a significant impact on the treatment of epilepsy. His patents reflect a deep understanding of the complexities of drug interactions and the need for careful patient management. Through his contributions, Checketts is helping to pave the way for new therapeutic options for patients suffering from epilepsy and related conditions.